These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

274 related items for PubMed ID: 17220325

  • 21. Risk of cervical intraepithelial neoplasia grade 2 or 3 after loop electrosurgical excision procedure associated with human papillomavirus type 16 variants.
    Xi LF, Kiviat NB, Wheeler CM, Kreimer A, Ho J, Koutsky LA.
    J Infect Dis; 2007 May 01; 195(9):1340-4. PubMed ID: 17397005
    [Abstract] [Full Text] [Related]

  • 22. Human papillomavirus type 18 DNA load and 2-year cumulative diagnoses of cervical intraepithelial neoplasia grades 2-3.
    Xi LF, Koutsky LA, Castle PE, Wheeler CM, Galloway DA, Mao C, Ho J, Kiviat NB.
    J Natl Cancer Inst; 2009 Feb 04; 101(3):153-61. PubMed ID: 19176451
    [Abstract] [Full Text] [Related]

  • 23. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice.
    Khan MJ, Castle PE, Lorincz AT, Wacholder S, Sherman M, Scott DR, Rush BB, Glass AG, Schiffman M.
    J Natl Cancer Inst; 2005 Jul 20; 97(14):1072-9. PubMed ID: 16030305
    [Abstract] [Full Text] [Related]

  • 24. Relationship between cigarette smoking and human papilloma virus types 16 and 18 DNA load.
    Xi LF, Koutsky LA, Castle PE, Edelstein ZR, Meyers C, Ho J, Schiffman M.
    Cancer Epidemiol Biomarkers Prev; 2009 Dec 20; 18(12):3490-6. PubMed ID: 19959700
    [Abstract] [Full Text] [Related]

  • 25. Cervical adenocarcinoma in situ: Human papillomavirus types and incidence trends in five states, 2008-2015.
    Cleveland AA, Gargano JW, Park IU, Griffin MR, Niccolai LM, Powell M, Bennett NM, Saadeh K, Pemmaraju M, Higgins K, Ehlers S, Scahill M, Johnson Jones ML, Querec T, Markowitz LE, Unger ER, HPV-IMPACT Working Group.
    Int J Cancer; 2020 Feb 01; 146(3):810-818. PubMed ID: 30980692
    [Abstract] [Full Text] [Related]

  • 26. Three-year longitudinal data on the clinical performance of the Abbott RealTime High Risk HPV test in a cervical cancer screening setting.
    Poljak M, Oštrbenk A, Seme K, Šterbenc A, Jančar N, Vrtačnik Bokal E.
    J Clin Virol; 2016 Mar 01; 76 Suppl 1():S29-S39. PubMed ID: 26643051
    [Abstract] [Full Text] [Related]

  • 27. Type-specific oncogenic human papillomavirus infection in high grade cervical disease in New Zealand.
    Simonella LM, Lewis H, Smith M, Neal H, Bromhead C, Canfell K.
    BMC Infect Dis; 2013 Mar 03; 13():114. PubMed ID: 23452957
    [Abstract] [Full Text] [Related]

  • 28. Recurrent high-grade cervical lesion after primary conization is associated with persistent human papillomavirus infection in Norway.
    Vintermyr OK, Iversen O, Thoresen S, Quint W, Molijn A, de Souza S, Rosillon D, Holl K.
    Gynecol Oncol; 2014 May 03; 133(2):159-66. PubMed ID: 24631451
    [Abstract] [Full Text] [Related]

  • 29. [To analyse the histopathological results of patients with HPV16/18 positive and colposcopic suspicious lesions].
    Zhang JX, Zheng TP, Liu J, Wang QX, Zhan YX, Zhang ZY.
    Zhonghua Fu Chan Ke Za Zhi; 2017 Jul 25; 52(7):467-472. PubMed ID: 28797154
    [Abstract] [Full Text] [Related]

  • 30. Changes in DNA Level of Oncogenic Human Papillomaviruses Other Than Types 16 and 18 in Relation to Risk of Cervical Intraepithelial Neoplasia Grades 2 and 3.
    Xi LF, Schiffman M, Hughes JP, Galloway DA, Koutsky LA, Kiviat NB.
    Cancer Epidemiol Biomarkers Prev; 2019 Aug 25; 28(8):1388-1394. PubMed ID: 31101617
    [Abstract] [Full Text] [Related]

  • 31. Multiple human papillomavirus infection with or without type 16 and risk of cervical intraepithelial neoplasia among women with cervical cytological abnormalities.
    Spinillo A, Gardella B, Roccio M, Alberizzi P, Cesari S, Patrizia M, Silini E.
    Cancer Causes Control; 2014 Dec 25; 25(12):1669-76. PubMed ID: 25296710
    [Abstract] [Full Text] [Related]

  • 32. Safety of extending screening intervals beyond five years in cervical screening programmes with testing for high risk human papillomavirus: 14 year follow-up of population based randomised cohort in the Netherlands.
    Dijkstra MG, van Zummeren M, Rozendaal L, van Kemenade FJ, Helmerhorst TJ, Snijders PJ, Meijer CJ, Berkhof J.
    BMJ; 2016 Oct 04; 355():i4924. PubMed ID: 27702796
    [Abstract] [Full Text] [Related]

  • 33. Efficacy of the AS04-Adjuvanted HPV16/18 Vaccine: Pooled Analysis of the Costa Rica Vaccine and PATRICIA Randomized Controlled Trials.
    Tota JE, Struyf F, Sampson JN, Gonzalez P, Ryser M, Herrero R, Schussler J, Karkada N, Rodriguez AC, Folschweiller N, Porras C, Schiffman M, Schiller JT, Quint W, Kreimer AR, Wheeler CM, Hildesheim A, Costa Rica Vaccine Trial and PATRICIA Study.
    J Natl Cancer Inst; 2020 Aug 01; 112(8):818-828. PubMed ID: 31697384
    [Abstract] [Full Text] [Related]

  • 34. Differences in human papillomavirus type distribution in high-grade cervical intraepithelial neoplasia and invasive cervical cancer in Europe.
    Tjalma WA, Fiander A, Reich O, Powell N, Nowakowski AM, Kirschner B, Koiss R, O'Leary J, Joura EA, Rosenlund M, Colau B, Schledermann D, Kukk K, Damaskou V, Repanti M, Vladareanu R, Kolomiets L, Savicheva A, Shipitsyna E, Ordi J, Molijn A, Quint W, Raillard A, Rosillon D, De Souza SC, Jenkins D, Holl K, HERACLES/SCALE Study Group.
    Int J Cancer; 2013 Feb 15; 132(4):854-67. PubMed ID: 22752992
    [Abstract] [Full Text] [Related]

  • 35. Association of HPV16 E6 variants with diagnostic severity in cervical cytology samples of 354 women in a US population.
    Zuna RE, Moore WE, Shanesmith RP, Dunn ST, Wang SS, Schiffman M, Blakey GL, Teel T.
    Int J Cancer; 2009 Dec 01; 125(11):2609-13. PubMed ID: 19569178
    [Abstract] [Full Text] [Related]

  • 36. Type-dependent association between risk of cervical intraepithelial neoplasia and viral load of oncogenic human papillomavirus types other than types 16 and 18.
    Fu Xi L, Schiffman M, Ke Y, Hughes JP, Galloway DA, He Z, Hulbert A, Winer RL, Koutsky LA, Kiviat NB.
    Int J Cancer; 2017 Apr 15; 140(8):1747-1756. PubMed ID: 28052328
    [Abstract] [Full Text] [Related]

  • 37. Long-term risk of cervical intraepithelial neoplasia grade 3 or worse according to high-risk human papillomavirus genotype and semi-quantitative viral load among 33,288 women with normal cervical cytology.
    Thomsen LT, Frederiksen K, Munk C, Junge J, Iftner T, Kjaer SK.
    Int J Cancer; 2015 Jul 01; 137(1):193-203. PubMed ID: 25471319
    [Abstract] [Full Text] [Related]

  • 38. Ten-year follow-up of human papillomavirus vaccine efficacy against the most stringent cervical neoplasia end-point-registry-based follow-up of three cohorts from randomized trials.
    Lehtinen M, Lagheden C, Luostarinen T, Eriksson T, Apter D, Harjula K, Kuortti M, Natunen K, Palmroth J, Petäjä T, Pukkala E, Siitari-Mattila M, Struyf F, Nieminen P, Paavonen J, Dubin G, Dillner J.
    BMJ Open; 2017 Aug 18; 7(8):e015867. PubMed ID: 28821519
    [Abstract] [Full Text] [Related]

  • 39. Association of cervical precancer with human papillomavirus types other than 16 among HIV co-infected women.
    Massad LS, Xie X, Burk RD, D'Souza G, Darragh TM, Minkoff H, Colie C, Burian P, Palefsky J, Atrio J, Strickler HD.
    Am J Obstet Gynecol; 2016 Mar 18; 214(3):354.e1-6. PubMed ID: 26433170
    [Abstract] [Full Text] [Related]

  • 40. Prevalence of Human Papillomavirus Genotypes Among Women With High-Grade Cervical Lesions in Beijing, China.
    Xiao M, Xu Q, Li H, Gao H, Bie Y, Zhang Z.
    Medicine (Baltimore); 2016 Jan 18; 95(3):e2555. PubMed ID: 26817906
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.